- Home
- Services
- north america
- hematopoietic stem cells
Show results for
Refine by
Hematopoietic Stem Cells Services In North America
7 services found
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
The traditional tumor target paradigm aims to treat hematological malignancies such as acute myeloid leukemia (AML) by focusing on the specificity and potency of therapies that kill cancer cells expressing a target. However, this paradigm is limited by the expression of tumor targets on healthy cells, resulting in on-target toxicity. On-target toxicity has led to the development failure of many ...
Manufactured by:Creative Bioarray based inShirley, NEW YORK (USA)
Human CD34+ Progenitor Cells, a transmembrane glycoprotein expressed on the surface of hematopoietic progenitor cells and small vascular endothelial cells, is considered to be a marker of hematopoietic stem cells and hematopoietic progenitor ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Bone marrow deficiency refers to a condition in which the hematopoietic stem cells in the bone marrow fail to produce enough, or produce abnormal, red blood cells, white blood cells and platelets. Hematopoietic cell transplantation (HCT), the transplantation of multipotent ...
Manufactured by:Creative Biogene based inShirley, NEW YORK (USA)
MMLV retrovirus has been broadly used for gene transduction in a variety of cells. However, expression of genes mediated by MMLV retrovirus can be repressed in many cell types including embryonic stem (ES), embryonal carcinoma (EC) and hematopoietic stem (HS) cells. The transcriptional repression ...
Manufactured by:Creative Bioarray based inShirley, NEW YORK (USA)
Bone Marrow CD133+ Stem/Progenitor Cells (also known as Prominin-1 or AC133) has been identified as an important cell surface marker. Cells expressing the CD133 marker are commonly referred to as primitive hematopoietic stem and progenitor cells (HSCs and HPCs). While ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Graft Versus Host Disease (GvHD) is a potentially lethal complication of hematopoietic cell transplantation (HCT) from a donor. When a patient receives a donor’s stem cells, the transplanted cells may identify the patient’s body as foreign and attack it. The chronic form of GvHD occurs at least 100 ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for major markets including the United States, Europe, Japan and ...